Working… Menu

Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02295969
Recruitment Status : Completed
First Posted : November 20, 2014
Last Update Posted : July 26, 2017
Venn Life Sciences
Information provided by (Responsible Party):
Stallergenes Greer

Brief Summary:
Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.

Condition or disease Intervention/treatment
Allergy Drug: Oralair

Detailed Description:

The purpose of this study is to further describe the safety and tolerability of ORALAIR tablets in children 5 to 9 years of age with grass-pollen-induced allergic rhinitis with or without conjunctivitis.

Patients are followed for safety and tolerability during the first 30 treatment days.

Layout table for study information
Study Type : Observational
Actual Enrollment : 307 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Study of ORALAIR® (Grass Pollen Allergen Extract From: Cocksfoot, Sweet Vernal, Rye Grass, Meadow Grass, Timothy) Tablet for Sublingual Use in Children 5 to 9 Years of Age With Grass-pollen-induced Allergic Rhinitis With or Without Conjunctivitis
Study Start Date : December 2014
Actual Primary Completion Date : July 3, 2017
Actual Study Completion Date : July 3, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pinkeye

Intervention Details:
  • Drug: Oralair
    Observational study, Oralair is used as prescribed by the prescriber phycisian.

Primary Outcome Measures :
  1. All adverse events that started on or after the day the first dose of Oralair [ Time Frame: During 30 days after the date of the first dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 9 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Outpatients, children 5 to 9 years of age prescribed ORALAIR for the treatment of grass-pollen-induced allergic rhinitis with or without conjunctivitis.

Inclusion Criteria:

Allergen immunotherapy naive male or female outpatients aged 5 to 9 years (inclusive) prescribed ORALAIR.

Exclusion Criteria:

Patients already participating in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02295969

Layout table for location information
Klinikum Augsburg, Klinik für Kinder und Jugendliche
Augsburg, Bavaria, Germany, 86156
Sponsors and Collaborators
Stallergenes Greer
Venn Life Sciences
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Stallergenes Greer Identifier: NCT02295969    
Other Study ID Numbers: SL74.14
First Posted: November 20, 2014    Key Record Dates
Last Update Posted: July 26, 2017
Last Verified: July 2017
Keywords provided by Stallergenes Greer:
Grass pollen
Sublingual tablet
Allergen immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Conjunctival Diseases
Eye Diseases